 Home > Active Ingredient News > Drugs Articles > UCB's innovative treatment for psoriasis obtains EU approval

UCB's innovative treatment for psoriasis obtains EU approval

 Last Update: 2021-09-12
 Source: Internet
 Author: User

Tags

hydrofluoric acid treatment

burkholderia cepacia treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, UCB announced that the European Commission has approved the company's development of Bimzelx (bimekizumab) for the treatment of patients with moderate to severe plaque psoriasis suitable for systemic treatment
.

The press release states that this is the first IL-17A/IL-17F inhibitor approved for the treatment of psoriasis

The fully humanized monoclonal antibody bimekizumab can strongly and specifically neutralize IL-17A and IL-17F
.

IL-17A plays a key role in the pathogenesis of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis

▲Schematic diagram of the working mechanism of Bimekizumab (picture source: reference [2])

This approval was supported by three phase 3 clinical trials BE VIVID, BE READY and BE SURE, involving 1,480 patients with moderate to severe psoriasis
.

All studies reached the common primary endpoint and critical secondary endpoint of the trial

(The original text has been deleted)

Reference materials:

[1] UCB Announces European Commission Approval of BIMZELX[®]▼ (bimekizumab) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Top Product

$1.6-1.65/G FOB

P-tolylacetic acid

CAS No.: 622-47-9

Industrial Grade or Medical grade

$1/MT EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.